<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684632</url>
  </required_header>
  <id_info>
    <org_study_id>2246-0702</org_study_id>
    <nct_id>NCT00684632</nct_id>
  </id_info>
  <brief_title>A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients</brief_title>
  <official_title>A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine whether KW-2246 is superior to placebo and not inferior&#xD;
      to immediate-release morphine for the relief of breakthrough pain in cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Pain, Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KW-2246</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-2246 (fentanyl citrate)</intervention_name>
    <description>KW-2246 (fentanyl citrate)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        At the time of obtaining written informed consent&#xD;
&#xD;
          -  Provide written informed consent to participate in the study on a voluntary basis.&#xD;
&#xD;
          -  Between the ages of 20 and 80 years (inclusive).&#xD;
&#xD;
          -  Outpatients who live with a caregiver such as a family member, or inpatients.&#xD;
&#xD;
          -  Regularly receiving one of the following opioid analgesics: sustained-release oral&#xD;
             morphine, sustained-release oral oxycodone, and fentanyl transdermal patch.&#xD;
&#xD;
          -  The daily dosage of the regular opioid analgesic regimen can be maintained constant&#xD;
             from the baseline period through the end of the study as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Require rescue medication at least 0.5 times (at least once every two days) but not&#xD;
             more than three times per day on average as determined by the investigator.&#xD;
&#xD;
          -  Performance Status (ECOG) of 3 or less at the time of giving written informed&#xD;
             consent.Be able to receive diary training and have the ability to properly complete&#xD;
             diaries as determined by the investigator.&#xD;
&#xD;
          -  Have a life expectancy of at least three months as determined by the investigator.&#xD;
&#xD;
          -  Be able to receive diary training and have the ability to properly complete diaries as&#xD;
             determined by the investigator.&#xD;
&#xD;
        At the time of randomization&#xD;
&#xD;
          -  The &quot;regular opioid analgesic&quot; being used at the time of giving written informed&#xD;
             consent has been taken at a fixed dosage throughout the baseline period.&#xD;
&#xD;
          -  The &quot;immediate-release morphine&quot; being used at the time of giving written informed&#xD;
             consent (OpsoÂ® (morphine hydrochloride hydrate) oral solution, morphine hydrochloride&#xD;
             (powder), or morphine hydrochloride tablets) has been taken at a fixed dosage of 5,&#xD;
             10, 15, or 20 mg/dose throughout the baseline period.&#xD;
&#xD;
          -  Have received rescue medication at least 0.5 times but not more than three times per&#xD;
             day on average during the baseline period.&#xD;
&#xD;
          -  Have had a pain intensity of at least 3 cm as rated on a visual analog scale (VAS)&#xD;
             immediately before each of two or more rescue doses of immediate-release morphine&#xD;
             during the baseline period, and had a mean decrease of at least 1.8 cm and at least&#xD;
             one-third in VAS-rated pain intensity at 30 minutes after dosing compared with the&#xD;
             pre-dose value.&#xD;
&#xD;
          -  Have received diary training and been able to properly complete diaries during the&#xD;
             baseline period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        At the time of obtaining written informed consent&#xD;
&#xD;
          -  Intolerable adverse reactions (as defined in Attachment 3) to opioids.&#xD;
&#xD;
          -  Serious respiratory dysfunction.&#xD;
&#xD;
          -  Asthma.&#xD;
&#xD;
          -  Serious bradyarrhythmia.&#xD;
&#xD;
          -  Serious hepatic dysfunction.&#xD;
&#xD;
          -  Serious renal dysfunction.&#xD;
&#xD;
          -  Susceptibility to respiratory depression due to conditions such as increased&#xD;
             intracranial pressure, head injury and brain tumor.&#xD;
&#xD;
          -  Patients who have a history of clinically significant adverse reactions to the&#xD;
             combination of opioid analgesics and any of the following drugs/substances, and who&#xD;
             are currently receiving or expect to receive any of them during the study:&#xD;
&#xD;
        Central nervous system depressants (phenothiazines, benzodiazepines and barbiturates),&#xD;
        inhalation anesthetics, monoamine oxidase inhibitors, tricyclic antidepressants, skeletal&#xD;
        muscle relaxants, antihistamines, ritonavir, alcohol, itraconazole, amiodarone,&#xD;
        clarithromycin, diltiazem, and fluvoxamine.&#xD;
&#xD;
          -  History of convulsive seizures (except a single episode of infantile febrile&#xD;
             convulsions).&#xD;
&#xD;
          -  History of hypersensitivity to fentanyl.&#xD;
&#xD;
          -  Current or past history of drug dependence or narcotic abuse.&#xD;
&#xD;
          -  Pregnant or lactating women, possibly pregnant women, or women who are planning to&#xD;
             become pregnant.&#xD;
&#xD;
          -  Participation in any other clinical trial within 28 days prior to giving written&#xD;
             informed consent.&#xD;
&#xD;
          -  Prior exposure to KW-2246.&#xD;
&#xD;
          -  Patients who are judged by the investigator/subinvestigator to be inappropriate for&#xD;
             this study.&#xD;
&#xD;
        At the time of randomization&#xD;
&#xD;
          -  Have experienced intolerable adverse reactions (as defined in Attachment 3) to opioids&#xD;
             during the baseline period.&#xD;
&#xD;
          -  Have received, during the baseline period, any morphine, oxycodone and fentanyl&#xD;
             formulations other than the &quot;regular opioid analgesic&quot; being used at the time of&#xD;
             giving written informed consent.&#xD;
&#xD;
          -  Use of codeine, dihydrocodeine, opium, pethidine, buprenorphine, pentazocine,&#xD;
             tramadol, butorphanol, and eptazocine within seven days prior to randomization (except&#xD;
             codeine at daily dosages up to 60 mg and dihydrocodeine at daily dosages up to 30 mg&#xD;
             for the treatment of cough).&#xD;
&#xD;
          -  Interventions that may affect pain intensity rating, such as surgery, radiation&#xD;
             therapy and nerve bThe daily dosages of systemically-acting adjuvant analgesics or&#xD;
             drugs with analgesic activity have been modified during the baseline period.lock,&#xD;
             within seven days prior to randomization.&#xD;
&#xD;
          -  Use of narcotic antagonists within seven days prior to randomization.&#xD;
&#xD;
          -  The daily dosages of systemically-acting adjuvant analgesics or drugs with analgesic&#xD;
             activity have been modified during the baseline period.&#xD;
&#xD;
          -  The daily dosages of locally-acting adjuvant analgesics or drugs with analgesic&#xD;
             activity being used for the relief of cancer pain have been modified during the&#xD;
             baseline period.&#xD;
&#xD;
          -  The daily dosages of codeine (up to 60 mg/day) and dihydrocodeine (up to 30 mg/day)&#xD;
             being used for the treatment of cough have been modified during the baseline period.&#xD;
&#xD;
          -  Have the following results in the most recent laboratory tests conducted within seven&#xD;
             days prior to randomization:&#xD;
&#xD;
        AST &gt;5 times the upper limit of normal at each study site (ULN); ALT &gt;5 times ULN; or Serum&#xD;
        creatinine &gt;1.5 times ULN.&#xD;
&#xD;
          -  Dry mouth that affects sublingual administration (i.e., poor compliance during&#xD;
             sublingual administration training with placebo).&#xD;
&#xD;
          -  Subjects who are judged by the investigator/subinvestigator to be inappropriate for&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kyowa Kirin Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katori</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koriyama</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uji</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Azumino</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ibaraki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumisano</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mibu</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain, cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breakthrough Pain</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

